Description
Valiltramiprosate is a prodrug of tramiprosate. It has been found to reduce plasma p-tau181 and to decrease amyloid-induced brain neurodegeneration.
Valiltramiprosate
Product ID V014451
Cas No. 1034190-08-3
Purity ≥99%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1034190-08-3 |
|---|---|
| Purity | ≥99% |
| Formula | C8H18N2O4S |
| Formula Wt. | 238.30 |
| IUPAC Name | 3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid |
| Synonym | ALZ-801 |
Shipping and Storage
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Hey J, Yu J, Abushakra S, et at. Clinical pharmacokinetics of oral ALZ-801/valiltramiprosate in a 2-year phase 2 trial of APOE4 carriers with early Alzheimer’s disease. Clin Pharmacokinet. 2025 Feb 5. PMID: 39907966.
Hey J, Abushakra S, Blennow K, et al. Effects of oral ALZ-801/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer’s disease. Drugs. 2024 Jul;84(7):811-823. PMID: 38902571.
Lee D, Antonsdottir I, Clark E, et al. Review of valiltramiprosate (ALZ-801) for the treatment of Alzheamier’s disease: a novel small molecule with disease modifying potential. Expert Opin Pharmacother. 2024 May;25(7):791-799. PMID: 38814590.